公开(公告)号：US20060241037A1

公开(公告)日：2006-10-26

申请号：US10568330

申请日：2004-08-25

申请人： Orest Olejnik ,  Peter Bakhit ,  Richard Graham ,  Jie Shen ,  Devin Welty ,  Diane Tang-Liu

发明人： Orest Olejnik ,  Peter Bakhit ,  Richard Graham ,  Jie Shen ,  Devin Welty ,  Diane Tang-Liu

IPC分类号： A61K38/17 ,  A61K31/4439

CPC分类号： A61K38/22 ,  A61K31/4439 ,  A61K45/06 ,  A61K2300/00

摘要： Disclosed are methods of preventing or treating a disease or adverse condition affecting the gastrointestinal tract of a mammal which comprise orally administering to a mammal a therapeutically effective amount of a prodrug of a proton pump inhibitor and an effective amount of a trefoil family factor peptide, mucoadhesive agent, or a combination thereof. Also disclosed are compositions which are suitable for use in a pharmaceutical dosage form. These compositions comprise a prodrug of a proton pump inhibitor, and also comprise a trefoil family factor peptide, a mucoadhesive component, or a combination thereof.

摘要翻译： 公开了预防或治疗影响哺乳动物胃肠道的疾病或不良状况的方法，其包括向哺乳动物施用治疗有效量的质子泵抑制剂的前药和有效量的三叶因子家族因子肽，粘膜粘附 代理或其组合。 还公开了适用于药物剂型的组合物。 这些组合物包含质子泵抑制剂的前体药物，并且还包括三叶族家族因子肽，粘膜粘附成分或其组合。

公开(公告)号：US20050075371A1

公开(公告)日：2005-04-07

申请号：US10943411

申请日：2004-09-17

申请人： Jie Shen ,  Devin Welty ,  Diane Tang-Liu

发明人： Jie Shen ,  Devin Welty ,  Diane Tang-Liu

IPC分类号： A61K31/44 ,  A61K31/4439 ,  A61P1/04

CPC分类号： A61K31/4439

摘要： Oral dosage forms, methods of treating diseases or adverse conditions, and methods of inhibiting gastric acid secretion related to prodrugs of a proton pump inhibitor are disclosed herein. Certain embodiments relate to the membrane permeability of the proton pump inhibitor and/or the membrane permeability of the prodrug. Other embodiments relate to prodrugs comprising an acidic functional group and a sulfonyl moiety. In other embodiments, the prodrug is a carboxylic acid which comprises a phenylsulfonyl moiety. Other embodiments relate to the pH of dosage forms and dosage forms comprising salts of acidic functional groups.

摘要翻译： 本文公开了口服剂型，治疗疾病或不利条件的方法，以及抑制与质子泵抑制剂前药有关的胃酸分泌的方法。 某些实施方案涉及质子泵抑制剂的膜渗透性和/或前药的膜渗透性。 其它实施方案涉及包含酸性官能团和磺酰基部分的前药。 在其它实施方案中，前药是包含苯磺酰基部分的羧酸。 其它实施方案涉及包含酸性官能团的盐的剂型和剂型的pH。

公开(公告)号：US20060182781A1

公开(公告)日：2006-08-17

申请号：US11368845

申请日：2006-03-06

申请人： Patrick Hughes ,  Joan-En Chang-Lin ,  Devin Welty

发明人： Patrick Hughes ,  Joan-En Chang-Lin ,  Devin Welty

IPC分类号： A61F2/00

CPC分类号： A61F9/00781 ,  A61F2210/0004 ,  A61K9/0051 ,  A61K9/1647 ,  A61K31/00

摘要： Biocompatible microparticles include a ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-oil emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

摘要翻译： 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物，当放置在结膜下空间中时，有利于将脂质组分释放到眼睛的前部和后部段中延长的时间。 环状脂质组分可与可生物降解的聚合物基质相结合，例如两种可生物降解聚合物的基质。 或者，环状脂质组分可以被聚合物组分包封。 本发明的微粒包括油包水乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。